Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2591 total matches.
Durysta - A Bimatoprost Implant for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
(Rhopressa)1 can be added
or substituted if IOP fails to reach the target range
with a PGA alone.2 Improper ...
The FDA has approved an intracameral implant
containing the prostaglandin analog bimatoprost
(Durysta – Allergan) for reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension. Bimatoprost is also
available in 0.01% (Lumigan) and 0.03% (generics)
ophthalmic solutions for the same indication and in
a 0.03% solution (Latisse, and generics) for eyelash
enhancement. Durysta is the first ocular implant to
become available in the US for treatment of glaucoma.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
,
blunted affect).1 Second-generation antipsychotic
drugs are generally used for initial treatment ...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
corticosteroid
deflazacort (Emflaza) were approved earlier.1,2
THE DISORDER — DMD is a progressive, X-linked ...
Golodirsen (Vyondys 53 — Sarepta), an antisense
oligonucleotide, has received accelerated approval
from the FDA for treatment of Duchenne muscular
dystrophy (DMD) in the ~8% of patients who have
mutations of the dystrophin gene that are amenable
to exon 53 skipping. It is the first drug to be approved
for this indication and the third to be approved for
treatment of DMD; the antisense oligonucleotide
eteplirsen (Exondys 51) and the oral corticosteroid
deflazacort (Emflaza) were approved earlier.
IV Meloxicam (Anjeso) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
in efficacy and safety to other NSAIDs.1 It has COX-2
selectivity in vitro, which decreases at higher ...
The FDA has approved Anjeso (Baudax Bio), an IV
formulation of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam, for once-daily treatment
of moderate to severe pain in adults. Oral meloxicam
(Mobic, and others), which is only indicated
for treatment of chronic pain associated with
osteoarthritis or rheumatoid arthritis, has been
available for 20 years. IV formulations of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain.
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
diabetes and established cardiovascular
disease (CVD) or multiple cardiovascular risk factors,1,2
has now ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease
(CVD) or multiple cardiovascular risk factors, has
now been approved for a third indication: to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in patients with heart failure
with reduced ejection fraction (with or without
type 2 diabetes). It is the first SGLT2 inhibitor to...
Melatonin for Insomnia in Children
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
sundown, reaches a peak between 2 AM
and 4 AM, and decreases gradually thereafter.1
PRODUCTS — Melatonin ...
Over-the-counter products containing melatonin are
widely used as sleep aids in children and adults.
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
)
was the first.1
Table 1. Pharmacology
Class Orexin receptor antagonist
Formulation 5, 10 mg tablets
Route ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
into (or first
appearing in) adulthood or even old age.1,2
NONPHARMACOLOGIC THERAPY
Skin hydration (a daily ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Eptinezumab (Vyepti) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
once monthly (fremanezumab
can also be given once every 3 months), were
approved earlier.1 ...
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth monoclonal
antibody to be approved for this indication; erenumab
(Aimovig), fremanezumab (Ajovy), and galcanezumab
(Emgality), which are all given subcutaneously once
monthly (fremanezumab can also be given once every 3
months), were approved earlier.
Talicia - A 3-Drug Combination for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
patient adherence to multidrug
regimens.1 When available, susceptibility testing
should be used to guide ...
The FDA has approved a fixed-dose combination
of omeprazole, amoxicillin, and rifabutin (Talicia –
RedHill) for treatment of Helicobacter pylori infection
in adults. Talicia is the first rifabutin-based product to
be approved for this indication.